Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Zacks Small Cap cut their FY2024 earnings per share estimates for Achieve Life Sciences in a report issued on Monday, November 11th. Zacks Small Cap analyst J. Vandermosten now expects that the biopharmaceutical company will post earnings of ($1.04) per share for the year, down from their prior forecast of ($0.89). The consensus estimate for Achieve Life Sciences' current full-year earnings is ($1.17) per share.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.10). During the same quarter in the prior year, the company posted ($0.34) earnings per share.
A number of other equities analysts also recently weighed in on ACHV. Oppenheimer reissued an "outperform" rating and set a $11.00 price target on shares of Achieve Life Sciences in a research report on Thursday, August 15th. Raymond James began coverage on Achieve Life Sciences in a report on Friday, September 27th. They set a "strong-buy" rating and a $20.00 price target for the company.
Check Out Our Latest Stock Analysis on Achieve Life Sciences
Achieve Life Sciences Price Performance
ACHV traded down $0.12 on Wednesday, hitting $4.53. 155,004 shares of the company were exchanged, compared to its average volume of 139,944. Achieve Life Sciences has a 12 month low of $3.03 and a 12 month high of $5.98. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. The stock's fifty day moving average is $4.71 and its 200-day moving average is $4.77.
Hedge Funds Weigh In On Achieve Life Sciences
A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Achieve Life Sciences by 56.6% during the first quarter. Vanguard Group Inc. now owns 948,441 shares of the biopharmaceutical company's stock worth $4,311,000 after buying an additional 342,731 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Achieve Life Sciences in the 1st quarter valued at approximately $59,000. Renaissance Technologies LLC boosted its stake in shares of Achieve Life Sciences by 134.2% in the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company's stock valued at $118,000 after purchasing an additional 14,360 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Achieve Life Sciences in the 2nd quarter valued at approximately $69,000. Finally, SG Americas Securities LLC acquired a new stake in Achieve Life Sciences during the 3rd quarter worth approximately $54,000. 33.52% of the stock is owned by institutional investors.
About Achieve Life Sciences
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Featured Articles
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
